pphm's trials are almost all ISTs since they are putting their limited resources toward nsclc p3, and as such, last week's PR is only intended to be an indicator.
are IST's supposed to spend the big bucks before they get indications from smaller, less complex trials?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.